Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma

MANNHEIM, Germany, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced three abstracts on two of its innate cell engagers (ICE) are accepted for presentation at the 66th ASH Annual Meeting and Exposition taking place December 7-10, 2024, in San Diego, California. An oral presentation will feature clinical results including promising efficacy and safety data from the AFM28 phase 1 dose escalation study in relapsed/refractory acute myeloid leukemia (AML). A poster with preclinical data will highlight the in vitro efficacy of AFM28 in combination with both patient-derived autologous NK cells and healthy volunteer-derived allogeneic NK cells against leukemic blasts.

Updated clinical results from all 4 cohorts of the run-in phase from the LuminICE-203 study evaluating acimtamig (AFM13) in combination with AlloNK (AB-101) for relapsed/ refractory Hodgkin Lymphoma will be shared in a poster session.

Details for the oral presentation and poster sessions are as follows:

Abstract Title	Date / Time / Presenter	Session Name / Location
“Investigating the Novel Combination of the Innate Cell Engager (ICE) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study”	December 8, 2024 6:00 PM - 8:00 PM PT Joseph Maakaron, MD Division of Hematology, Oncology and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA	Session Name: 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster II Location: San Diego Convention Center, Halls G-H Publication Number: 3052
“Engaging Innate Immunity by AFM28, an Innate Cell Engager (ICE) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study”	December 9, 2024